The Safety and Immune Response to Influenza Vaccination in Pregnant Women

Phase 4

Completed

• Conditions: Influenza
• Interventions: Biological: AdimFlu-S Influenza Vaccine

• Registration Number: NCT01514708
• Lead Sponsor: Adimmune Corporation

Brief Summary

The purpose of this study is to evaluate the antibody response to the influenza vaccine (AdimFlu-S), as measured by hemagglutination inhibition (HAI) at 4 weeks post immunization in pregnant women in compliance with the requirements of the current European Union (EU) recommendations for the evaluation of the immunogenicity for a new formulation of a licensed flu vaccine (CPMP/BWP/214/96). Besides, the vaccine safety will also be evaluated.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-11
• Study First Submitted: 2012-01-18
• Study First Submitted QC: 2012-01-18
• Study First Posted: 2012-01-23
• Primary Completion: 2012-06
• Study Completion: 2012-08
• Status Verified: 2012-12
• Last Update Submitted: 2018-07-12
• Last Update Posted: 2018-07-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 46

Inclusion Criteria

1. Pregnant female aged ≥ 18 years old.
2. Subject is pregnant for at least 3 months, inclusive.
3. Subject is willing and able to adhere to visit schedules and all study requirements.
4. Subject has read and signed the study-specific informed consent.

Exclusion Criteria

1. Subject with previous complicated pregnancy or preterm delivery, spontaneous or medical abortion;
2. Subject with history or concurrent high risk of dangerous gestation such as gestational diabetes mellitus (GDM), pregnant induced hypertension, or preeclampsia;
3. Subject received any influenza vaccine within the previous 6 months;
4. Subject has a history of hypersensitivity to eggs or egg protein or similar pharmacological effects to study vaccine;
5. Subject or her family has the history of Guillain-Barré Syndrome;
6. Subject has current upper respiratory illness (URI), including the common cold or nasal congestion within 72 hours;
7. Subject with influenza-like illness as defined by the presence of fever (temperature over 38ºC) and at least two of the following four symptoms: headache, muscle/joint aches and pains (e.g. myalgia/arthralgia), sore throat and cough;
8. Subject receive any treatment with an investigational drug or device, or participation in a clinical study, within 3 months before consent;
9. Subject has immunodeficiency or is under immunosuppressive treatment.
10. Subject received any vaccine within 1 week prior to study vaccination or expected to receive one within 1 week after study vaccination;
11. Subject received any blood products, including immunoglobulin, in the past 3 months before consent;
12. Subject has underlying condition in the investigators' opinion may interfere with evaluation of the vaccine;

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
AdimFlu-S Influenza Vaccine, 0.5mL/dose, receive 1 dose	AdimFlu-S Influenza Vaccine	-

Primary Outcome Measures

Name	Time	Method
The primary endpoint will be the seroprotection rate which is defined as the proportion of subjects with HAI titer ≥ 1:40. The other immunogenicity endpoints include seroconversion rate and geometric mean folds increase in HAI titer.	Immunogenicity profile was assessed before vaccination, 4 weeks after the vaccination and at the end of gestation period. Moreover, the HAI titer of the cord blood was also measured and compared with the maternal blood sample.	The primary endpoint will be the seroprotection rate which is defined as the proportion of subjects with HAI titer ≥ 1:40. The other immunogenicity endpoints include seroconversion rate and geometric mean folds increase in HAI titer. Immunogenicity profile will be assessed before vaccination, 4 weeks after the vaccination and at the end of gestation period.

Secondary Outcome Measures

Name	Time	Method
The secondary endpoint is to evaluate the safety and tolerability profiles including the presence or absence of the pre-specified reactogenicity events and other serious/non-serious adverse events of the AdimFlu-S.	The safety information is collected from the day of vaccination to 8 weeks after the delivery.	Safety outcomes include immediate reactions at the time of vaccination, solicited local and systemic reactions for 7 days, unsolicited adverse events until the first post-vaccination serum collected (Day 28), and serious adverse events and adverse events of special interest until 8 weeks after the delivery.

Trial Locations

Locations (1)

National Taiwan University Hospital; 🇨🇳 Taipei, Taiwan